

EMPAVELI® (pegcetacoplan) Injection, for Subcutaneous Use

Company: Apellis Pharmaceuticals, Inc

Product name: EMPAVELI

Generic name: pegcetacoplan

Indication: EMPAVELI is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).¹



PRODUCT SPECIFICATIONS

How Supplied¹	EMPAVELI injection is a clear, colorless to slightly yellowish aqueous solution for subcutaneous infusion supplied as 1080 mg/20 mL (54 mg/mL) solution in 20 mL single-dose vials
Packaging¹	A carton containing 8 individually packaged 20 mL single-dose vials (4-week supply)
Storage¹	Refrigerate vials at 36 °F to 46 °F (2 °C to 8 °C) in the original carton
Distribution	PANTHERx and other REMS-certified pharmacies will dispense EMPAVELI, along with ancillary supplies, to the patient. Patients using the EMPAVELI Injector will receive a single-use, disposable, on-body injector supplied in boxes of 8 to align with twice-weekly dosing. Patients using an infusion pump will receive 1 infusion pump with the first shipment
Equipment and Ancillary Supplies	<ul style="list-style-type: none">○ EMPAVELI Injector²○ Ancillaries: sterile 20 mL syringe, needleless transfer device, alcohol wipes²○ Sharps container² <hr/> <ul style="list-style-type: none">○ Commercially available infusion pump³○ Ancillaries: needle set, compatible syringe, infusion tubing, vial adapter, alcohol wipes, gauze, and tape³○ Sharps container³
REMS¹	Prescribers must enroll in the EMPAVELI REMS program
NDC Number¹	73606-010-01
ICD-10 Code⁴	D59.5



Here for your patients

ApellisAssist is a program designed to help your patients along their treatment journey. ApellisAssist can be reached at 1-866-MY-APL-ASSIST (1-866-692-7527) from 8 AM-8 PM ET, Monday-Friday.

ICD-10=International Classification of Diseases, Tenth Revision; NDC=national drug code; REMS=risk evaluation and mitigation strategy.

INDICATION

EMPAVELI® (pegcetacoplan) is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* type B.

- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.
- Vaccinate patients at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection.
- Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected.

EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program.

Please see Important Safety Information throughout, full Prescribing Information, including **BOXED WARNING** regarding serious infections caused by encapsulated bacteria, and Medication Guide.

 **EMPAVELI**[®]
(pegcetacoplan) injection
1080 mg/20 mL solution

IMPORTANT SAFETY INFORMATION (cont'd)

CONTRAINDICATIONS

- Hypersensitivity to pegcetacoplan or to any of the excipients
- Not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying EMPAVELI treatment outweigh the risks of developing a bacterial infection with an encapsulated organism
- Unresolved serious infection caused by encapsulated bacteria including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae*

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

The use of EMPAVELI may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI.

For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI REMS

Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program and must counsel patients about the risk of serious infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com.

Infusion-Related Reactions

Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Please see Important Safety Information throughout, full Prescribing Information, including BOXED WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

 **EMPAVELI**[®]
(pegcetacoplan) injection
1080 mg/20 mL solution

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Monitoring PNH Manifestations after Discontinuation of EMPAVELI

After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

Most common adverse reactions in patients with PNH (incidence $\geq 10\%$) were injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash.

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including **BOXED WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.**

References: 1. Empaveli. Prescribing information. Apellis Pharmaceuticals, Inc; 2023. 2. Empaveli Injector. Instructions for use. Apellis Pharmaceuticals, Inc; 2023. 3. Empaveli. Instructions for use. Apellis Pharmaceuticals, Inc; 2023. 4. ICD-10-CM code D59.5. ICD.Codes. Accessed October 25, 2023. <https://icd.codes/icd10cm/D595#:~:text=5%20is%20a%20billable%20ICD,to%20specify%20a%20medical%20diagnosis>



APELLIS, APELLISASSIST, EMPAVELI, and their respective logos are trademarks of Apellis Pharmaceuticals, Inc. Other trademarks referenced herein are the property of their respective owners.

©2023 Apellis Pharmaceuticals, Inc. All rights reserved. 11/23 US-PEGPNH-2300141 v1.0

